Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Nov 24, 2025; 16(11): 110687
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.110687
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.110687
Clinical outcomes of early-stage breast cancer in Morocco: A cohort of 400 women
Nabil Ismaili, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca 20100, Morocco
Nabil Ismaili, Fadila Guessous, Sanaa El Majjaoui, Laboratory of Oncopathology, Biology and Environment of Cancer Laboratory, Mohammed VI Center for Research and Innovation, Rabat 10100, Morocco
Fadila Guessous, Department of Biomedical Sciences, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca 20100, Morocco
Sanaa El Majjaoui, Department of Radiotherapy, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca 20100, Morocco
Author contributions: Ismaili N was responsible for the conception and design, data collection and assembly, data analysis, interpretation, manuscript writing, and final approval of the manuscript; Guessous F was responsible for the interpretation, manuscript writing, and final approval of the manuscript; El Majjaoui S was responsible for the data collection and assembly, interpretation, manuscript writing, and final approval of manuscript.
Institutional review board statement: The Institutional Review Board of the Mohammed VI University of Sciences and Health confirms that the present retrospective study, involving human subjects, ensure the protection of participants’ identity and data confidentiality.
Informed consent statement: As the treatment was conducted by the medical staff, depending on the drugs availability in Morocco, oral consent was obtained from the subjects and was approved by the Institutional Review Boards of the National Institute of Oncology Cancer Center in Rabat.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors who contributed to this manuscript.
Data sharing statement: The data supporting the study findings is accessible for review at National Institute of Oncology in Rabat.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nabil Ismaili, MD, Professor, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health, Boulevard Mohamed Taieb Naciri, Commune Hay Hassani, Casablanca 20100, Morocco.
Received: June 17, 2025
Revised: July 8, 2025
Accepted: October 9, 2025
Published online: November 24, 2025
Processing time: 158 Days and 0.1 Hours
Revised: July 8, 2025
Accepted: October 9, 2025
Published online: November 24, 2025
Processing time: 158 Days and 0.1 Hours
Core Tip
Core Tip: In this retrospective study, we investigated demographics, tumor characteristics, and outcomes in women with early breast cancer in a cohort of 400 Moroccan women. At a median follow-up of 74.5 months, the 5-year overall survival (OS) was 82.1%, and the 5-year disease-free survival was estimated at 78.1%. In univariate analysis, patients with negative pathologic nodal stage and American Joint Committee on Cancer (AJCC) stage I-II had better OS than those with pN+ and stage III disease, respectively. In multivariate analysis, AJCC stage I-II (vs stage III) showed the strongest association with improved OS, followed by treatment with anthracyclines (vs cyclophosphamide, methotrexate and fluorouracil).